Article Sidebar
Views pdf: 28
Views pdf: 0
EVALUATE EXPRESSION OF HEXOKINASE 2 AT mRNA LEVEL IN LYMPHOMA PATIENTS
Main Article Content
Abstract
Enzyme HK2 plays important role in glucose metabolism pathway and has been associated with several cancers in progression and development. However, the expression of HK2 at mRNA in peripheral blood of lymphoma patients have never been mentioned. Our study was conducted to evaluate HK2 expression at mRNA level in control-case study. The results of counting the number of total white blood cells, neutrophil and lymphocyte were increased in the lymphoma groups whereas decreased in eosinophil (p<0.05), no significant in basophils and monocytes (p>0.05) compared with healthy controls group. Notably, HK2 expression in lymphoma patients was significantly lower than healthy individuals. Our study suggests the role of HK2 in lymphoma formation and is a potential biomarker in diagnosis and assessment of treatment effectiveness.
Article Details
Keywords
: Hexokinase 2, lymphoma, mRNA
References
2. Jiao L, Zhang HL, Li DD, et al. Regulation of glycolytic metabolism by autophagy in liver cancer involves selective autophagic degradation of HK2 (hexokinase 2). Autophagy. 2018;14(4):671-684. doi:10.1080/15548627.2017.1381804
3. Patra KC, Wang Q, Bhaskar PT, et al. Hexokinase 2 Is Required for Tumor Initiation and Maintenance and Its Systemic Deletion Is Therapeutic in Mouse Models of Cancer. Cancer Cell. 2013;24(2):213-228. doi:10.1016/j.ccr.2013. 06.014
4. Porrata LF, Ristow K, Colgan JP, et al. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin’s lymphoma. Haematologica. 2012;97(2):262-269. doi:10.3324/haematol.2011.050138
5. Jin J, Gui A, Chen G, et al. Hexokinase II expression as a prognostic marker in diffuse large B-cell lymphoma: pre- and post-rituximab era. Int J Hematol. 2022;116(3): 372-380. doi:10.1007/ s12185-022-03358-0
6. Lin J, Fang W, Xiang Z, et al. Glycolytic enzyme HK2 promotes PD-L1 expression and breast cancer cell immune evasion. Front Immunol. 2023;14: 1189953. doi:10.3389/fimmu. 2023.1189953
7. Nakajima K, Kawashima I, Koshiisi M, et al. Glycolytic enzyme hexokinase II is a putative therapeutic target in B-cell malignant lymphoma. Experimental Hematology. 2019;78:46-55.e3. doi:10.1016/j.exphem.2019.09.023
8. Zhao H, Xiang G, Shao T, Wang M, Dai W. HK2 contributes to the proliferation, migration, and invasion of diffuse large B-cell lymphoma cells by enhancing the ERK1/2 signaling pathway. Open Life Sci. 2023; 18(1):20220726. doi:10. 1515/biol-2022-0726